Hyperlipidemia, Hypertension, Metabolic Syndrome X, Obesity
Conditions
Keywords
Obesity,, Metabolic Syndrome,, BMI
Brief summary
The purpose of this trial is to study the safety, tolerability and efficacy of an almond enriched hypocaloric diet on weight loss and weight maintenance, as well as on established and emerging cardiovascular risk factors in approximately 112 overweight and obese persons.
Detailed description
A randomized, non-blinded, controlled clinical trial using a parallel design of a hypocaloric, low fat (\<30% energy from fat) diet with or without 2 oz of almonds over 18 months. Interim analyses will be conducted at 3, 6, 9 and 12 months. The study will be divided into 3 phases. Phase 1 (months 0-6) will be an active, intensive weight loss phase. During phase 1, all subjects will meet once a week in the evening for 1.5 hours. Phase 2 (months 6-12) will be a less intensive weight loss phase. During phase 2 groups will meet every other week in the evening for 1.5 hours. The last phase will be the weight maintenance phase or phase 3 (months 12-18).
Interventions
BEHAVIORALAlmond enriched diet
Subjects will consume 2 oz. of almond per day in addition to a low-fat diet
BEHAVIORALLow fat caloric diet
Low fat caloric diet
Sponsors
Almond Board of California
Temple University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Body mass index (BMI) \> 27 but \<40 * 18-75 years of age * Men and non-pregnant or lactating women * Subjects must be willing to comply with all study-related procedures
Exclusion criteria
* Uncontrolled hypertension * Diabetes or use of anti-hyperglycemic medication * Dyslipidemia requiring prescription drug therapy as defined by NCEP ATPIII guidelines at screening * Known allergy or sensitivity to nuts * Known atherosclerotic cardiovascular disease * History of congestive heart failure * History of a non-skin malignancy within the previous 5 years * Any major active rheumatologic, pulmonary, hepatic, renal, dermatologic disease or inflammatory condition * History of being HIV positive * History of alcohol or drug abuse * Weight-loss inducing medications or dietary supplements within 3 months prior to enrollment. * Weight loss \> 5 kg during the last 6 months * Participation in an investigational drug study within 6 weeks prior to screening * Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effects of an almond-enriched (2 oz/day) hypocaloric, low-fat diet on body weight and body composition in overweight and obese persons | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the effects of the almond enriched diet on established and emerging surrogate markers of coronoary artery disease (CAD) risk | 6 months |
Countries
United States
Outcome results
None listed